Bausch Health Companies Inc. BHC.TO

Company Overview

Bausch Health Companies Inc. is a diversified specialty pharmaceutical and healthcare company headquartered in Laval, Québec, Canada. The company develops, manufactures, and markets prescription drugs, over-the-counter products, and medical devices across several therapeutic areas, including gastroenterology, ophthalmology, dermatology, neurology, and aesthetics. Bausch Health operates primarily through branded pharmaceutical and medical device businesses and generates revenue from product sales across both mature and growth-oriented healthcare markets.

The company’s principal operating businesses include Salix Pharmaceuticals, Bausch + Lomb, International Pharmaceuticals, and Solta Medical. Historically known as Valeant Pharmaceuticals, the company rebranded to Bausch Health in 2018 following a period of restructuring and strategic repositioning focused on operational stability, debt reduction, and investment in core healthcare franchises. A significant strategic advantage has been its portfolio of established specialty brands with strong physician relationships and global distribution capabilities, particularly in eye health and gastroenterology.

Business Operations

Bausch Health organizes its operations through several major business segments. Salix Pharmaceuticals focuses on gastrointestinal treatments and generates revenue through products such as Xifaxan and other GI-focused therapies primarily in the United States. Bausch + Lomb, which became a separately traded public company while remaining majority-owned by Bausch Health for a period following its 2022 IPO, operates globally in eye health products including contact lenses, surgical devices, and ophthalmic pharmaceuticals. The company also operates an International Pharmaceuticals segment serving markets in Europe, Latin America, the Middle East, Africa, and Asia-Pacific, as well as Solta Medical, which provides energy-based aesthetic medical devices.

Revenue is derived primarily from pharmaceutical product sales, medical device sales, licensing arrangements, and international distribution. The company maintains manufacturing, research, and distribution facilities across multiple regions and controls a broad portfolio of intellectual property tied to branded pharmaceuticals and device technologies. Key subsidiaries and affiliated businesses include Salix Pharmaceuticals, Bausch + Lomb, and Solta Medical. Bausch Health has historically relied on strategic licensing partnerships, commercialization agreements, and acquisitions to expand therapeutic reach and geographic scale.

Strategic Position & Investments

Bausch Health’s strategic direction has centered on strengthening core therapeutic franchises, reducing leverage, and improving operational efficiency. In recent years, management has emphasized investment in gastroenterology, eye health, and aesthetics while streamlining non-core assets. The partial separation and public listing of Bausch + Lomb represented one of the company’s most significant strategic transactions, intended to unlock shareholder value and provide greater financial flexibility.

The company has also invested in product lifecycle management, international expansion, and targeted innovation within specialty pharmaceuticals and medical devices. Solta Medical has expanded Bausch Health’s exposure to non-invasive aesthetic technologies, while continued investment in gastrointestinal treatments through Salix Pharmaceuticals remains a key growth initiative. Public filings and investor materials indicate ongoing prioritization of debt reduction and disciplined capital allocation following years of acquisition-driven expansion under the former Valeant structure.

Geographic Footprint

Bausch Health operates in more than 90 countries, with major commercial operations across North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa. The company’s corporate headquarters are located in Laval, Québec, while significant operational infrastructure exists in the United States, particularly through its pharmaceutical and eye health businesses.

Its international business includes pharmaceutical sales, medical device distribution, manufacturing operations, and regional commercial partnerships. Bausch + Lomb has historically provided one of the company’s broadest global footprints through ophthalmology products distributed across developed and emerging healthcare markets. The company’s diversified regional exposure helps mitigate dependence on any single market, although the United States remains its largest source of revenue.

Leadership & Governance

Bausch Health’s leadership has focused on operational restructuring, debt management, and long-term portfolio optimization. The company’s governance approach has emphasized compliance, disciplined financial oversight, and rebuilding investor confidence following the controversies associated with the Valeant era. Strategic leadership has also prioritized strengthening core healthcare franchises while improving transparency with shareholders and regulators.

Key executives include:

• Thomas J. Appio – Chief Executive Officer
• Sam Eldessouky – Executive Vice President and Chief Financial Officer
• Paul S. Herendeen – Former Executive Vice President and Chief Financial Officer
• Christophe Dalbon – Executive Vice President, General Counsel and Corporate Secretary
• Brent Saunders – Former Chairman and Chief Executive Officer
• Joseph C. Papa – Former Chairman and Chief Executive Officer

The company’s leadership transition over recent years has reflected a broader strategic shift away from aggressive acquisition-led growth toward operational execution, deleveraging, and sustainable development within specialty healthcare markets.